enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment...
16 insider purchases on record · latest filing 2026-09-24.
Insiders have also filed 3 sale transactions at ENGN.